Although orally administered SGLT2 inhibitors have been demonstrated to exhibit several favorable effects in the clinical course of T2D and heart failure patients, their rationale has not yet been proven in well-designed randomized controlled trials nor for patients suffering from LCS; however, especially for those living with LCS, this information is crucial and urgently needed. Here, SLC5A2 is linked to type 2 diabetes mellitus.